Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) — Net Asset Quality Index
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) has a Net Asset Quality Index of 94.2% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥6.02 Billion minus total liabilities of CN¥347.84 Million yields net assets of CN¥5.67 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check earnings quality score of Wuhan Easy Diagnosis Biomedicine Co Ltd to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Net Asset Quality Index Over Time (2011–2025)
This chart shows how Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the index stands at 94.2%, representing net assets of CN¥5.67 Billion against total assets of CN¥6.02 Billion CNY. See net assets of Wuhan Easy Diagnosis Biomedicine Co Ltd for net asset value and shareholders' equity analysis.
Annual Net Asset Quality Index for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (2011–2025)
The table below presents the year-by-year Net Asset Quality Index for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Wuhan Easy Diagnosis Biomedicine Co Ltd market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 94.6% | CN¥5.66 Billion | CN¥5.98 Billion | CN¥324.56 Million | ▲ +3.3 pp |
| 2024 | 91.3% | CN¥6.02 Billion | CN¥6.59 Billion | CN¥574.40 Million | ▲ +6.1 pp |
| 2023 | 85.2% | CN¥6.29 Billion | CN¥7.39 Billion | CN¥1.09 Billion | ▲ +11.5 pp |
| 2022 | 73.7% | CN¥6.77 Billion | CN¥9.19 Billion | CN¥2.42 Billion | ▼ -9.7 pp |
| 2021 | 83.4% | CN¥2.85 Billion | CN¥3.42 Billion | CN¥567.02 Million | ▲ +5.3 pp |
| 2020 | 78.1% | CN¥1.11 Billion | CN¥1.43 Billion | CN¥311.77 Million | ▼ -18.3 pp |
| 2019 | 96.4% | CN¥615.62 Million | CN¥638.42 Million | CN¥22.80 Million | ▲ +0.4 pp |
| 2018 | 96.0% | CN¥592.59 Million | CN¥617.15 Million | CN¥24.55 Million | ▲ +1.3 pp |
| 2017 | 94.7% | CN¥242.93 Million | CN¥256.54 Million | CN¥13.60 Million | ▲ +5.9 pp |
| 2016 | 88.8% | CN¥175.08 Million | CN¥197.15 Million | CN¥22.07 Million | ▲ +2.7 pp |
| 2015 | 86.1% | CN¥115.39 Million | CN¥133.96 Million | CN¥18.57 Million | ▲ +4.9 pp |
| 2014 | 81.3% | CN¥49.59 Million | CN¥61.01 Million | CN¥11.42 Million | ▲ +24.1 pp |
| 2013 | 57.1% | CN¥13.60 Million | CN¥23.79 Million | CN¥10.19 Million | ▲ +26.6 pp |
| 2012 | 30.6% | CN¥1.42 Million | CN¥4.66 Million | CN¥3.23 Million | ▲ +29.5 pp |
| 2011 | 1.1% | CN¥21.45K | CN¥1.96 Million | CN¥1.94 Million | — |